Your browser is no longer supported. Please, upgrade your browser.
Settings
KERX Keryx Biopharmaceuticals, Inc. daily Stock Chart
KERX [NASD]
Keryx Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own0.90% Shs Outstand123.79M Perf Week-4.97%
Market Cap804.64M Forward P/E- EPS next Y-0.32 Insider Trans-2.18% Shs Float117.42M Perf Month-6.07%
Income-185.00M PEG- EPS next Q-0.18 Inst Own67.50% Short Float13.47% Perf Quarter-10.84%
Sales42.80M P/S18.80 EPS this Y-28.40% Inst Trans0.08% Short Ratio13.36 Perf Half Y11.49%
Book/sh0.23 P/B28.26 EPS next Y74.00% ROA-119.00% Target Price8.00 Perf Year40.09%
Cash/sh1.13 P/C5.73 EPS next 5Y- ROE- 52W Range4.11 - 8.38 Perf YTD10.92%
Dividend- P/FCF- EPS past 5Y-29.30% ROI-103.90% 52W High-22.43% Beta5.15
Dividend %- Quick Ratio5.20 Sales past 5Y44.90% Gross Margin-1.00% 52W Low58.15% ATR0.32
Employees193 Current Ratio5.80 Sales Q/Q62.40% Oper. Margin- RSI (14)38.05 Volatility4.15% 4.33%
OptionableYes Debt/Eq4.93 EPS Q/Q-82.10% Profit Margin- Rel Volume0.84 Prev Close6.46
ShortableYes LT Debt/Eq4.93 EarningsNov 08 BMO Payout- Avg Volume1.18M Price6.50
Recom2.40 SMA20-8.50% SMA50-8.09% SMA2002.05% Volume995,846 Change0.62%
May-08-17Reiterated Maxim Group Buy $7 → $9
Jan-11-17Upgrade Citigroup Sell → Neutral
Nov-09-16Upgrade Maxim Group Hold → Buy $7
Aug-02-16Downgrade Stifel Buy → Hold
Aug-02-16Downgrade FBR Capital Outperform → Mkt Perform $16 → $7
Aug-02-16Downgrade Brean Capital Buy → Hold
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-08-16Reiterated Maxim Group Buy $7 → $9
Mar-30-16Reiterated FBR Capital Outperform $10 → $13
Feb-29-16Upgrade FBR Capital Mkt Perform → Outperform $10
Feb-26-16Upgrade Raymond James Mkt Perform → Outperform
Feb-26-16Reiterated Stifel Buy $10 → $9
Feb-26-16Downgrade JP Morgan Overweight → Neutral
Feb-25-16Reiterated Maxim Group Buy $11 → $5
Oct-05-15Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-09-15Initiated Raymond James Mkt Perform
Sep-03-15Initiated Citigroup Sell
Aug-13-15Initiated Morgan Stanley Underweight $3
Aug-11-15Initiated FBR Capital Mkt Perform $10
Aug-10-15Downgrade ROTH Capital Buy → Neutral $11 → $6
Oct-16-17 08:35AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 16, 2017 Capital Cube
Oct-13-17 10:11AM  Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting GlobeNewswire
Oct-10-17 01:19PM  Before You Buy Keryx Biopharmaceuticals Incs (KERX), You Should Consider This Simply Wall St.
07:19AM  Why the Bears Are Wrong About Keryx Biopharmaceuticals Stock Motley Fool
Oct-05-17 08:25AM  Keryx, Upcoming PDUFA Action on Label Expansion for Auryxia ACCESSWIRE
Sep-29-17 09:13AM  Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat Zacks
Sep-28-17 10:15AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : September 28, 2017 Capital Cube
Sep-26-17 08:12AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : September 26, 2017 Capital Cube
Sep-25-17 08:57AM  Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised) Zacks
Sep-20-17 11:17AM  Here's Why These 3 Biotech Stocks Might Stop Rallying Zacks
Sep-18-17 08:39AM  Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9% Zacks
Sep-15-17 09:45AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : September 15, 2017 Capital Cube +5.89%
Sep-13-17 04:10PM  Keryx Biopharmaceuticals Announces Changes to its Board of Directors GlobeNewswire
Sep-05-17 08:01AM  Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 GlobeNewswire
Sep-01-17 11:40PM  Keryx Biopharmaceuticals, Inc. Value Analysis (NASDAQ:KERX) : September 2, 2017 Capital Cube +5.41%
Aug-29-17 08:39AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : August 29, 2017 Capital Cube
Aug-13-17 08:15PM  Edited Transcript of KERX earnings conference call or presentation 27-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 05:47PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : August 11, 2017 Capital Cube
Aug-07-17 09:21AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : August 7, 2017 Capital Cube
Aug-04-17 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuitys 37th Annual Growth Conference on August 9, 2017 GlobeNewswire
Aug-02-17 08:15AM  3 Biotech Stocks With Big News Coming Motley Fool
Jul-28-17 01:36PM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
09:36AM  Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat Zacks
Jul-27-17 10:35PM  Keryx Biopharma reports 2Q loss Associated Press
02:21PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 27, 2017 Capital Cube
09:07AM  Keryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat Zacks
07:01AM  Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance GlobeNewswire
Jul-23-17 08:15AM  3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock) Motley Fool
Jul-21-17 11:51AM  What to Expect from Keryx (KERX) this Earnings Season? Zacks
Jul-20-17 08:49AM  Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX) SmarterAnalyst
Jul-19-17 08:31AM  Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017 GlobeNewswire -6.88%
Jul-17-17 01:46PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 17, 2017 Capital Cube
Jul-08-17 06:31AM  Why Keryx Biopharmaceuticals Stock Soared 11.6% Higher in June Motley Fool
Jul-05-17 12:51PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 5, 2017 Capital Cube
Jun-19-17 04:58PM  Keryx Biopharmaceuticals, Inc. Value Analysis (NASDAQ:KERX) : June 19, 2017 Capital Cube
Jun-16-17 08:37AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : June 16, 2017 Capital Cube
Jun-09-17 11:24AM  Keryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue? Zacks
May-30-17 09:01AM  Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies 2017 Healthcare Conference on June 6, 2017 GlobeNewswire
May-22-17 01:50PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 22, 2017 Capital Cube
May-19-17 08:00AM  Top 4 Pharmaceutical Stocks for 2017 Investopedia
May-11-17 04:59PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 08:55PM  Edited Transcript of KERX earnings conference call or presentation 4-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-09-17 11:10AM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-05-17 10:37AM  Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat Zacks +5.35%
08:00AM  Today's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals Accesswire
May-04-17 07:57AM  Keryx Biopharma reports 1Q loss Associated Press +6.56%
07:41AM  Keryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat Zacks
07:05AM  Investor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call Accesswire
07:02AM  Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results GlobeNewswire
May-01-17 07:40AM  Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans GlobeNewswire
Apr-28-17 06:07PM  What to Expect from Keryx (KERX) Stock This Earnings Season? Zacks
Apr-18-17 08:35AM  Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017 GlobeNewswire
Apr-10-17 09:35AM  Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation Accesswire
Apr-07-17 04:59PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : April 7, 2017 Capital Cube
09:02AM  Here's Why Keryx Biopharmaceuticals Jumped 27.3% in March Motley Fool
Apr-04-17 07:00AM  Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report? Zacks
07:00AM  Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report?
Mar-22-17 05:27PM  Keryx's Auryxia Added to Largest Medicare Part D Plan Zacks
05:27PM  Keryx's Auryxia Added to Largest Medicare Part D Plan
Mar-21-17 09:30AM  Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Accesswire -9.70%
Mar-20-17 07:30AM  Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies GlobeNewswire +7.89%
Mar-16-17 06:12PM  Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat Zacks
06:12PM  Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
Mar-09-17 08:15AM  Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets Accesswire
Mar-08-17 03:51PM  3 Top Stocks Under $5 Motley Fool
03:51PM  3 Top Stocks Under $5 at Motley Fool
07:30AM  Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets GlobeNewswire
Mar-07-17 01:55PM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
01:55PM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
01:04PM  KERYX BIOPHARMACEUTICALS INC Financials
11:06AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Mar-02-17 04:51PM  Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat
Mar-01-17 06:40PM  Edited Transcript of KERX earnings conference call or presentation 1-Mar-17 1:00pm GMT
09:22AM  Keryx (KERX) Posts Wider-than-Expected Loss in Q4
08:00AM  Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
07:29AM  Keryx Biopharma reports 4Q loss
07:07AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q4 2016 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:51AM  Should You Sell Keryx Biopharmaceuticals (KERX) Before Earnings?
07:24AM  Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
07:17AM  Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More
Feb-27-17 08:21AM  Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
Feb-23-17 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017 GlobeNewswire
Feb-16-17 09:15AM  Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017 GlobeNewswire -7.97%
Feb-08-17 09:01AM  Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017 GlobeNewswire
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
Jan-23-17 12:02PM  Keryx Biopharmaceuticals, Inc. Value Analysis (NASDAQ:KERX) : January 23, 2017
Jan-20-17 08:31AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : January 20, 2017
Jan-13-17 06:13PM  Keryx Releases Auryxia Data for Iron Deficiency Anemia
Jan-12-17 09:54AM  Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology GlobeNewswire
Jan-11-17 06:24AM  Keryx Biopharma upgraded by Citigroup
Jan-09-17 08:32AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors o
Jan-08-17 06:00PM  Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-17 02:46PM  Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Lawsuit Business Wire
Jan-03-17 02:24PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : January 3, 2017
Dec-30-16 08:35AM  Implied Volatility Surging for Keryx (KERX) Stock Options
Dec-24-16 09:51AM  3 Companies Whose Revenue Could Double in 2017 at Motley Fool
Dec-22-16 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgans 35th Annual Healthcare Conference on January 11, 2017 GlobeNewswire
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has a license agreement with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Madison GregPresident and CEOOct 05Sale7.198956,435372,742Oct 06 05:25 PM
Adams BrianGeneral Counsel and SecretaryOct 05Sale7.196304,530135,420Oct 06 05:25 PM
Madison GregPresident and CEOJul 31Sale7.144,13129,495373,637Aug 01 04:32 PM
Adams BrianGeneral Counsel and SecretaryJul 31Sale7.141,44510,317136,050Aug 01 04:28 PM
Holmes Scott AChief Financial OfficerJul 31Sale7.141,44510,317142,282Aug 01 04:27 PM
Neylan John F.Chief Medical OfficerJul 31Sale7.141,44510,317126,585Aug 01 04:25 PM
Holmes Scott AChief Financial OfficerJul 28Sale6.961,2368,603143,727Jul 31 04:57 PM
Neylan John F.Chief Medical OfficerJul 24Sale7.271,2148,826128,030Jul 25 05:00 PM
Madison GregPresident and CEOJul 05Sale7.679106,980377,768Jul 06 06:05 PM
Adams BrianGeneral Counsel and SecretaryJul 05Sale7.676414,916137,495Jul 06 05:59 PM
Madison GregPresident and CEOMay 01Sale5.974,12224,608378,678May 03 04:06 PM
Adams BrianGeneral Counsel and SecretaryMay 01Sale5.971,4418,603138,136May 03 04:05 PM
Holmes Scott AChief Financial OfficerMay 01Sale5.971,4418,603144,963May 03 04:05 PM
Neylan John F.Chief Medical OfficerMay 01Sale5.971,4418,603129,244May 03 04:05 PM
Holmes Scott AChief Financial OfficerApr 28Sale5.891,2197,180146,404May 01 04:05 PM
Neylan John F.Chief Medical OfficerApr 24Sale5.731,2096,928130,685Apr 26 04:05 PM
Adams BrianGeneral Counsel and SecretaryApr 17Sale5.751,0906,268139,577Apr 18 04:05 PM
Adams BrianGeneral Counsel and SecretaryApr 05Sale5.806423,724140,667Apr 06 04:05 PM
Madison GregPresident and CEOApr 05Sale5.809115,284382,800Apr 06 04:05 PM
Madison GregPresident and CEOFeb 09Sale5.471,6118,812233,711Feb 13 04:18 PM
Madison GregPresident and CEOJan 30Sale4.6518,24884,853235,322Jan 31 04:05 PM
Holmes Scott AChief Financial OfficerJan 30Sale4.658,44739,27998,873Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 30Sale4.656,98432,47683,144Jan 31 04:05 PM
Adams BrianGeneral Counsel and SecretaryJan 30Sale4.656,98432,47692,559Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 23Sale5.391,4287,69790,128Jan 25 04:06 PM
Adams BrianVP and General CounselJan 17Sale6.241,2657,89499,543Jan 18 04:05 PM
Adams BrianVP and General CounselJan 05Sale6.167594,675100,808Jan 06 04:06 PM
Madison GregPresident and CEOJan 05Sale6.161,0776,634253,570Jan 06 04:05 PM
Madison GregPresident and CEONov 09Sale4.991,5597,779254,647Nov 14 04:06 PM
Holmes Scott AChief Financial OfficerOct 28Sale4.441,2375,492107,320Oct 31 04:07 PM
Neylan John F.Chief Medical OfficerOct 24Sale4.721,2115,71691,556Oct 25 04:05 PM